Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other financing activities (2016 - 2025)

Historic Other financing activities for Anika Therapeutics (ANIK) over the last 13 years, with Q3 2025 value amounting to $13000.0.

  • Anika Therapeutics' Other financing activities fell 3809.52% to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 3483.1%. This contributed to the annual value of $2.6 million for FY2024, which is 2077.14% up from last year.
  • Latest data reveals that Anika Therapeutics reported Other financing activities of $13000.0 as of Q3 2025, which was down 3809.52% from $83000.0 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Other financing activities registered a high of $2.3 million during Q1 2024, and its lowest value of -$218000.0 during Q4 2021.
  • Over the past 5 years, Anika Therapeutics' median Other financing activities value was $107000.0 (recorded in 2023), while the average stood at $440842.1.
  • The largest annual percentage gain for Anika Therapeutics' Other financing activities in the last 5 years was 162800.0% (2023), contrasted with its biggest fall of 70000.0% (2023).
  • Over the past 5 years, Anika Therapeutics' Other financing activities (Quarter) stood at -$218000.0 in 2021, then surged by 99.54% to -$1000.0 in 2022, then tumbled by 700.0% to -$8000.0 in 2023, then skyrocketed by 1050.0% to $76000.0 in 2024, then plummeted by 82.89% to $13000.0 in 2025.
  • Its Other financing activities stands at $13000.0 for Q3 2025, versus $83000.0 for Q2 2025 and $1.5 million for Q1 2025.